It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Genome-wide association studies have linked gene variants of the receptor patched homolog 1 (PTCH1) with chronic obstructive pulmonary disease (COPD). However, its biological role in the disease is unclear. Our objective was to determine the expression pattern and biological role of PTCH1 in the lungs of patients with COPD. Airway epithelial-specific PTCH1 protein expression and epithelial morphology were assessed in lung tissues of control and COPD patients. PTCH1 mRNA expression was measured in bronchial epithelial cells obtained from individuals with and without COPD. The effects of PTCH1 siRNA knockdown on epithelial repair and mucous expression were evaluated using human epithelial cell lines. Ptch1+/− mice were used to assess the effect of decreased PTCH1 on mucous expression and airway epithelial phenotypes. Airway epithelial-specific PTCH1 protein expression was significantly increased in subjects with COPD compared to controls, and its expression was associated with total airway epithelial cell count and thickness. PTCH1 knockdown attenuated wound closure and mucous expression in airway epithelial cell lines. Ptch1+/− mice had reduced mucous expression compared to wildtype mice following mucous induction. PTCH1 protein is up-regulated in COPD airway epithelium and may upregulate mucous expression. PTCH1 provides a novel target to reduce chronic bronchitis in COPD patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 St. Paul’s Hospital, Center for Heart Lung Innovation, Vancouver, Canada (GRID:grid.416553.0) (ISNI:0000 0000 8589 2327)
2 University of British Columbia, Biomedical Research Centre (BRC), Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830)
3 St. Paul’s Hospital, Center for Heart Lung Innovation, Vancouver, Canada (GRID:grid.416553.0) (ISNI:0000 0000 8589 2327); University of British Columbia, Department of Anaesthesiology, Pharmacology, & Therapeutics, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830)
4 University of British Columbia, Division of Respiratory Medicine, Department of Medicine, St. Paul’s Hospital, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830)
5 Merck & Co. Inc., Rahway, United States of America (GRID:grid.417993.1) (ISNI:0000 0001 2260 0793)